CATURANO, ALFREDO
 Distribuzione geografica
Continente #
EU - Europa 4.904
AS - Asia 2.337
NA - Nord America 1.647
SA - Sud America 347
AF - Africa 31
OC - Oceania 3
Totale 9.269
Nazione #
RU - Federazione Russa 4.008
US - Stati Uniti d'America 1.598
SG - Singapore 716
CN - Cina 503
VN - Vietnam 412
HK - Hong Kong 341
IT - Italia 298
BR - Brasile 280
IE - Irlanda 245
KR - Corea 116
DE - Germania 103
IN - India 97
GB - Regno Unito 69
JP - Giappone 37
FR - Francia 34
AR - Argentina 26
MX - Messico 23
NL - Olanda 19
ID - Indonesia 16
PL - Polonia 16
SE - Svezia 15
CA - Canada 13
FI - Finlandia 13
TR - Turchia 13
AT - Austria 12
ES - Italia 11
LT - Lituania 10
ZA - Sudafrica 10
BD - Bangladesh 9
EC - Ecuador 9
UA - Ucraina 9
CO - Colombia 8
VE - Venezuela 8
AE - Emirati Arabi Uniti 7
IQ - Iraq 7
PK - Pakistan 7
BE - Belgio 6
CZ - Repubblica Ceca 6
EG - Egitto 6
GR - Grecia 6
IL - Israele 6
IR - Iran 6
MA - Marocco 6
PE - Perù 6
SA - Arabia Saudita 6
CH - Svizzera 4
PT - Portogallo 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AU - Australia 3
AZ - Azerbaigian 3
BO - Bolivia 3
JO - Giordania 3
KG - Kirghizistan 3
LB - Libano 3
TW - Taiwan 3
UZ - Uzbekistan 3
BA - Bosnia-Erzegovina 2
CL - Cile 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
JM - Giamaica 2
LA - Repubblica Popolare Democratica del Laos 2
MO - Macao, regione amministrativa speciale della Cina 2
MY - Malesia 2
NP - Nepal 2
RO - Romania 2
RS - Serbia 2
SI - Slovenia 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
DM - Dominica 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
HN - Honduras 1
KW - Kuwait 1
LV - Lettonia 1
MD - Moldavia 1
MU - Mauritius 1
NO - Norvegia 1
PH - Filippine 1
PS - Palestinian Territory 1
PY - Paraguay 1
QA - Qatar 1
SN - Senegal 1
TH - Thailandia 1
TJ - Tagikistan 1
Totale 9.269
Città #
Moscow 1.441
Singapore 366
Hong Kong 331
San Jose 305
Dublin 231
Santa Clara 196
Hefei 138
Chandler 132
Ho Chi Minh City 122
Seoul 115
Ashburn 113
The Dalles 113
Hanoi 99
Naples 83
New York 67
Bengaluru 65
Beijing 44
Munich 42
Da Nang 37
Dallas 37
Los Angeles 33
São Paulo 30
Princeton 22
Roxbury 22
Cambridge 20
Haiphong 20
Orem 19
Falkenstein 15
Bremen 13
Chicago 13
Amsterdam 12
Hải Dương 12
Salerno 12
Atlanta 11
Caserta 11
Mexico City 11
Tokyo 11
Belo Horizonte 10
Chennai 10
Frankfurt am Main 10
Hillsboro 10
Stockholm 10
Avellino 9
Brooklyn 9
Milan 9
Biên Hòa 8
Boston 8
Istanbul 8
Manchester 8
Nuremberg 8
Warsaw 8
Bắc Ninh 7
Des Moines 7
Ercolano 7
Helsinki 7
Houston 7
Liveri 7
Bexley 6
Brussels 6
Denver 6
Florence 6
Guarulhos 6
Johannesburg 6
Lahore 6
Napoli 6
Rome 6
Boardman 5
Changsha 5
Council Bluffs 5
Curitiba 5
Damietta 5
Jacksonville 5
London 5
Nanjing 5
Nha Trang 5
Rio de Janeiro 5
Thanh Mỹ Tây 5
Vienna 5
Wroclaw 5
Baghdad 4
Brno 4
Can Tho 4
Cape Town 4
Columbus 4
Duncan 4
Giugliano in Campania 4
Ha Long 4
Lappeenranta 4
Lima 4
Lisbon 4
Montreal 4
Mumbai 4
Nonantola 4
Paris 4
Pelotas 4
Phoenix 4
Quito 4
San Francisco 4
Shenzhen 4
Tel Aviv 4
Totale 4.734
Nome #
Cardiac Hypertrophy: from Pathophysiological Mechanisms to Heart Failure Development 181
Association between Renal Function at Admission and COVID-19 in-Hospital Mortality in Southern Italy: Findings from the Prospective Multicenter Italian COVOCA Study 179
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease 162
Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study 155
ULTRASOUND TIPS IN THE LUNG CANCER DIAGNOSIS: A PILOT STUDY 155
Aspirin in a Diabetic Retinopathy Setting: insights from NO BLIND Study 152
Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes 150
Peripheral Neuropathy in Diabetes Mellitus: Pathogenetic Mechanisms and Diagnostic Options 149
Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options 149
Current Knowledge on the Pathophysiology of Lean/Normal-Weight Type 2 Diabetes 147
Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects? 143
Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study 138
Left bundle branch pacing and cardiac remodeling in HF patients with type 2 diabetes mellitus: epigenetic pathways and clinical outcomes 138
Comment on: Effect of Vitamin D supplementation in patients with liver cirrhosis having spontaneous bacterial peritonitis: a randomized controlled study 138
Cardiovascular benefits from gliflozins: Effects on endothelial function 134
Anti-Inflammatory and Anticancer Effects of Anticoagulant Therapy in Patients with Malignancy 133
HCC and molecular targeting therapies: Back to the future 133
Impact of Acute Kidney Injury on the COVID-19 In-Hospital Mortality in Octogenarian Patients: Insights from the COVOCA Study 131
An Update on Betrixaban, the Challenging Anticoagulant Agent for Extended Venous Thromboembolism Prophylaxis 130
Liver Involvement in Patients With Systemic Sclerosis: Role of Transient Elastography in the Assessment of Hepatic Fibrosis and Steatosis 128
Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study 127
Comment on: Warfarin adherence and anticoagulation control in atrial fibrillation patients-a systematic review 127
Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease 126
Impact of liver fibrosis on COVID-19 in-hospital mortality in Southern Italy 125
Alcohol Consumption and Liver Metabolism in the Era of MASLD: Integrating Nutritional and Pathophysiological Insights 122
Sex-difference of multifactorial intervention on cardiovascular and mortality risk in DKD: post-hoc analysis of a randomised clinical trial 122
The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial 122
CURRENT HEPATOCELLULAR CARCINOMA SYSTEMIC PHARMACOLOGICAL TREATMENT OPTIONS 122
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 122
EFFICACY OF COVID-19 VACCINATION IN PATIENTS WITH IMMUNE SYSTEM DISORDERS AND CANCER 120
Effects of Heart Failure Therapies on Atrial Fibrillation: Biological and Clinical Perspectives 117
Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes 116
Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence 115
Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies 115
Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications 115
The Lipid-Lowering Efficacy of a Nutraceutical Combination Including Leucoselect Phytosome, Red Yeast Rice, Policosanol and Folic Acid in Dyslipidaemia Patients: Real-World Insights 114
Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study 114
Effects of metformin in heart failure: From pathophysiological rationale to clinical evidence 113
Diabetic Gastroparesis: Navigating Pathophysiology and Nutritional Interventions 112
Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function 110
ULTRASOUND TIPS IN THE LUNG CANCER DIAGNOSIS: A PILOT STUDY 110
The prognostic role of interatrial block among COVID-19 patients hospitalized in medicine wards 109
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care 107
Assessment of the Effectiveness of Ticagrelor Preloading in Mitigating Periprocedural Myocardial Injury Among Non-ST Elevation Myocardial Infarction Patients Opting for an Early Invasive Approach 106
Polypharmacy and major adverse events in atrial fibrillation 105
Optimizing Anticoagulation Management in Atrial Fibrillation: Beyond the Guidelines. How and for Whom? 104
The Significance of Statin-Associated Muscle Symptoms and Its Impact on Patient Adherence and Outcomes 103
Serum Lipids, Inflammation, and the Risk of Atrial Fibrillation: Pathophysiological Links and Clinical Evidence 102
Brugada syndrome and COVID-19 vaccines 102
Late Hepatocellular Carcinoma Occurrence in Patients Achieving Sustained Virological Response After Direct-Acting Antiviral Therapy: A Matter of Follow-Up or Something Else? 100
The Importance of Telemedicine during COVID-19 Pandemic: A Focus on Diabetic Retinopathy 100
Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk 98
Predictive Value of Fatty Liver Index for Long-Term Cardiovascular Events in Patients Receiving Liver Transplantation: The COLT Study 97
NerveCheck master to screen patients with type 1 or type 2 diabetes for peripheral and cardiac autonomic neuropathy 97
Insulin resistance and cancer: molecular links and clinical perspectives 95
Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review 95
Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study 95
Long-term clinical outcomes of patients with drug-induced type 1 Brugada electrocardiographic pattern: A nationwide cohort registry study 94
Role of Albuminuria in Detecting Cardio-Renal Risk and Outcome in Diabetic Subjects 93
null 93
The Role of Neuropathy Screening Tools in Patients Affected by Fibromyalgia 93
Antioxidant and Antidiabetic Potential of the Antarctic Lichen Gondwania regalis Ethanolic Extract: Metabolomic Profile and In Vitro and In Silico Evaluation 92
Commentary on Antithrombotic Effect of Protopanaxatriol Saponins from Panax notoginseng Using Zebrafish Model 91
Insulin–Heart Axis: Bridging Physiology to Insulin Resistance 90
Clinical Utilization and Performance of Bempedoic Acid in an Italian Real-World Setting: Insight from Campania Region 89
High HDL Cholesterol: a risk factor for Diabetic Retinopathy? Findings from NO BLIND study 88
Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact 87
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms 87
Metabolic Rewiring of Bacterial Pathogens in Response to Antibiotic Pressure—A Molecular Perspective 86
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms 86
Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice 86
Clinical performance of subcutaneous vs. transvenous implantable defibrillator in patients with ischemic cardiomyopathy: data from Monaldi Rhythm Registry 85
Multidrug-Resistant Infections and Metabolic Syndrome: An Overlooked Bidirectional Relationship 84
Impact of Gliflozins on Right Heart Remodeling in Italian Patients with Type 2 Diabetes and Heart Failure: Results from the GLISCAR Real-World Study 81
Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations 79
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence 76
The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management 75
Right ventricular electrocardiographic abnormalities among hospitalized COVID-19 patients: Simple marker of worst clinical outcome 74
Metabolic Dysfunction-Associated Steatotic Liver Disease in Klinefelter Syndrome: High Prevalence Uncovers an Unmet Need 73
Remdesivir treatment and clinical outcome in non-severe hospitalized COVID-19 patients: a propensity score matching multicenter Italian hospital experience 70
Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad 69
Impact of empagliflozin as add-on to metformin vs metformin continuation on MASLD progression in type 2 diabetes: The IMAGIN Study 66
The Intestinal Thread of Fate: How the Microbiota Shapes the Story of Liver Disease 59
Editorial on: Canagliflozin Mediates Mitophagy Through the AMPK/PINK1/PARKIN Pathway to Alleviate Isoprenaline-Induced Cardiac Remodeling 58
Oral Anticoagulation for Atrial Fibrillation in Octogenarians Across the Renal Function Spectrum 53
When the dual-chamber pacing system is the optimal choice for Brugada patients in need of implantable cardiac defibrillator 52
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects 51
IMPACT OF EMPAGLIFLOZIN AND METFORMIN COMBINATION THERAPY VS. METFORMIN MONOTHERAPY ON MASLD PROGRESSION IN TYPE 2 DIABETES: FINDINGS FROM THE IMAGIN STUDY 6
IMPACT OF EMPAGLIFLOZIN AND METFORMIN COMBINATION THERAPY VS. METFORMIN MONOTHERAPY ON MASLD PROGRESSION IN TYPE 2 DIABETES: FINDINGS FROM THE IMAGIN STUDY 4
Totale 9.396
Categoria #
all - tutte 27.686
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.686


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202111 0 0 0 0 0 0 0 0 0 3 5 3
2021/2022197 11 1 8 19 33 8 4 4 11 16 29 53
2022/2023498 28 28 15 19 67 30 5 31 230 11 10 24
2023/2024363 34 17 13 25 77 63 9 9 8 28 30 50
2024/20251.341 13 17 5 26 204 140 209 124 194 115 119 175
2025/20266.952 369 429 375 300 634 3.680 476 306 266 117 0 0
Totale 9.396